Form D · Biotechnology
Panacent Bio Inc.
New York, NY · CIK 0002030065
Offering snapshot reported Jul 12, 2024 · SEC filing
- Reported sold
- $13 Offering amount: $13
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2024 | Initial | $13 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-518567
Source: Form D, filed Jul 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Charytonowicz | Executive |
| Robert Sebra | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
666 Greenwich Street 744
New York, NY, 10014
New York, NY, 10014